Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

Results: Safety Summary of Treatment Emergent AEs: no safety concern      ET D3ET D5Pooled D3 / D5 PlaceboNolasiban PlaceboNolasiban PlaceboNolasiban N=195N=193N=196N=194N=391N=387 Parameter SubjectsSubjects Subjects Subjects Subjects Subjects n(%)n(%)n(%)n(%)n(%)n(%) Any TEAE44 (23)34 (18)55 (28)51 (26)99(25)85(22) TEAE related to IMP02 (1)*02 (1)**04 (1) Serious TEAE2 (1)2 (1)7 (4)2 (1)9 (2)4 (1) Serious TEAE related to IMP000000 Fatal TEAE000000 Preliminary note:—Congenital malformation: Placebo: 1; Nolasiban: 1—Ectopic pregnancy: Placebo: 4; Nolasiban: 1 TEAE related to IMP (all mild): * Feeling hot; Urticaria    ** Dizziness; Headache